Understand Your Brain Health with CoGenesis Neurodegenerative Disorder Screening
Neurodegenerative diseases can develop silently over time — often showing symptoms only after irreversible damage has occurred. With CoGenesis Neurodegenerative Disorder Screening, you can take proactive steps toward early detection and better long-term care.
Our comprehensive test suite covers both common and rare neurological conditions, helping patients and healthcare providers make informed decisions at every stage.
Broad Genetic Screening for Neurological Conditions
CoGenesis Neuro screens for 505 genes associated with a wide range of neurodegenerative disorders, including Parkinson's disease, ALS, and hereditary spastic paraplegia.
CoGenesis Myopathy focuses on 108 genes related to various muscular and neuromuscular disorders, such as limb-girdle muscular dystrophy and congenital myopathies.
We also offer targeted testing for Spinocerebellar Ataxia (SCA) subtypes, allowing for accurate diagnosis of this complex group of inherited conditions.
Alzheimer’s Disease Detection – From Genetic Risk to Biomarkers
For individuals concerned about Alzheimer’s disease, our suite includes:
CoGenesis Alzheimer's Disease Genetic Testing, ideal for early-onset cases with strong family history
APOE genotyping to assess genetic risk
Blood-based biomarker testing, including p-Tau 217 and Aβ42/40, for non-invasive detection of late-onset Alzheimer’s
Using next-generation sequencing (NGS) and validated biomarker platforms, CoGenesis tests deliver fast, reliable, and clinically actionable results — even for complex or rare conditions.
Whether you're experiencing symptoms, have a family history, or simply want peace of mind, CoGenesis helps you stay one step ahead of neurodegeneration — through knowledge, early detection, and proactive care.
